Clinical Trials Logo
  1. Home
  2. Alcoholic Liver Disease
  3. NCT04858412

Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19

Alcoholic Liver Disease Clinical Trial

Official title:
Evaluate the Molecular Mechanisms of HMB-enriched Amino Acid Supplement to Reverse Muscle Loss in Patients With Alcoholic Liver Disease and COVID-19

Clinical Trial Summary

Patients with COVID-19 and comorbidities including alcohol associated liver disease (ALD) are at risk for severe illness and abrupt or sudden clinical deterioration with ventilatory failure. â-hydroxy â-methyl butyrate (HMB), a non-nitrogenous leucine metabolite with anabolic properties, increases muscle mass and contractile function and enhances immune function. We aim to study the natural course of COVID-19 in patients with ALD and test whether HMB can affect ventilatory deterioration and improve short and long-term morbidity, mortality, and recovery from critical illness in symptomatic COVID-19 patients with ALD.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04858412
Study type Interventional
Source The Cleveland Clinic
Contact Annette Bellar, MSLA
Phone 216-445-0688
Email bellara@ccf.org
Status Recruiting
Phase N/A
Start date April 1, 2021
Completion date March 31, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT00708617 - FIBROSCAN Validation and Interest of Fibrotest - FIBROSCAN Association for Fibrosis Diagnosis in Alcoholic Liver Disease N/A
Completed NCT00990639 - Effect of Candesartan in Alcoholic Liver Fibrosis Phase 1/Phase 2
Recruiting NCT04106518 - Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Recruiting NCT04666402 - Integrated Diagnostics for Early Diagnosis of Liver Disease
Recruiting NCT02331745 - RCT Study on Granulocyte Colony-stimulating Factor(G-CSF) Treatment of Hepatic Failure Phase 4
Completed NCT01501162 - Effect of Probiotics on Gut-Liver Axis of Alcoholic Liver Disease Phase 4
Recruiting NCT05895890 - French National MICMAF Cohort
Completed NCT04557774 - Cognitive Function of Alcoholic Compensated Liver Cirrhosis
Recruiting NCT03267069 - Evaluating Alcohol Use in Alcoholic Liver Disease
Recruiting NCT03295812 - Stratification of Chronic Alcoholic Liver Diseases (SCALE Study) N/A
Recruiting NCT05855031 - The Liver Care Trial N/A
Not yet recruiting NCT03503708 - Herbal Supplements for Improvement of Liver Function in Participants With Alcoholic Liver Disease N/A
Completed NCT02796469 - Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis N/A
Completed NCT02140294 - Long Term Effect of Aggressive Nutritional Management on Survival in Patients With Alcoholic Liver Disease N/A
Recruiting NCT03209791 - Ethanol Induces Skeletal Muscle Autophagy
Recruiting NCT04400604 - Study of Alcohol-related Liver Disease in Europe
Recruiting NCT04736966 - Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease Phase 1
Completed NCT03402256 - Text Messaging to Reduce Alcohol Relapse in Liver Transplant Patients N/A
Completed NCT01711125 - Baclofen in the Treatment of Alcohol Dependence With or Without Alcoholic Liver Disease Phase 3
Active, not recruiting NCT03863730 - Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota N/A